Subscription-Based Pricing for Lenacapavir-Learning From Hepatitis C and Cabotegravir

JAMA. 2026 Feb 10;335(6):485-486. doi: 10.1001/jama.2025.24404.

Authors

Michael R Rose¹, Charles Flexner¹, Victor Roy²

Affiliations

¹ Department of Medicine, Division of Clinical Pharmacology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
² Department of Family Medicine and Community Health, Leonard Davis Institute for Health Economics, University of Pennsylvania, Philadelphia.

PMID: 41499140
DOI: 10.1001/jama.2025.24404

No abstract available

Plain language summary

This Viewpoint discusses ways in which payer license agreements can facilitate widespread lenacapavir use, a key step in ending the HIV epidemic.